These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 9815561)

  • 1. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells.
    Aebi S; Fink D; Gordon R; Kim HK; Zheng H; Fink JL; Howell SB
    Clin Cancer Res; 1997 Oct; 3(10):1763-7. PubMed ID: 9815561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cells.
    Fink D; Nebel S; Norris PS; Aebi S; Kim HK; Haas M; Howell SB
    Br J Cancer; 1998 Mar; 77(5):703-8. PubMed ID: 9514047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of DNA mismatch repair in platinum drug resistance.
    Fink D; Nebel S; Aebi S; Zheng H; Cenni B; Nehmé A; Christen RD; Howell SB
    Cancer Res; 1996 Nov; 56(21):4881-6. PubMed ID: 8895738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of DNA mismatch repair in acquired resistance to cisplatin.
    Aebi S; Kurdi-Haidar B; Gordon R; Cenni B; Zheng H; Fink D; Christen RD; Boland CR; Koi M; Fishel R; Howell SB
    Cancer Res; 1996 Jul; 56(13):3087-90. PubMed ID: 8674066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents.
    Brown R; Hirst GL; Gallagher WM; McIlwrath AJ; Margison GP; van der Zee AG; Anthoney DA
    Oncogene; 1997 Jul; 15(1):45-52. PubMed ID: 9233776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apoptosis induced by overexpression of hMSH2 or hMLH1.
    Zhang H; Richards B; Wilson T; Lloyd M; Cranston A; Thorburn A; Fishel R; Meuth M
    Cancer Res; 1999 Jul; 59(13):3021-7. PubMed ID: 10397236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
    Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
    Vaisman A; Varchenko M; Umar A; Kunkel TA; Risinger JI; Barrett JC; Hamilton TC; Chaney SG
    Cancer Res; 1998 Aug; 58(16):3579-85. PubMed ID: 9721864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance to topoisomerase poisons due to loss of DNA mismatch repair.
    Fedier A; Schwarz VA; Walt H; Carpini RD; Haller U; Fink D
    Int J Cancer; 2001 Aug; 93(4):571-6. PubMed ID: 11477562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells.
    Jacob S; Aguado M; Fallik D; Praz F
    Cancer Res; 2001 Sep; 61(17):6555-62. PubMed ID: 11522654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of H(2)O(2) on cell cycle and survival in DNA mismatch repair-deficient and -proficient cell lines.
    Chang DK; Goel A; Ricciardiello L; Lee DH; Chang CL; Carethers JM; Boland CR
    Cancer Lett; 2003 Jun; 195(2):243-51. PubMed ID: 12767533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells.
    Nehmé A; Baskaran R; Nebel S; Fink D; Howell SB; Wang JY; Christen RD
    Br J Cancer; 1999 Mar; 79(7-8):1104-10. PubMed ID: 10098743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Msh2 deficiency does not contribute to cisplatin resistance in mouse embryonic stem cells.
    Claij N; te Riele H
    Oncogene; 2004 Jan; 23(1):260-6. PubMed ID: 14712231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin.
    Moreland NJ; Illand M; Kim YT; Paul J; Brown R
    Cancer Res; 1999 May; 59(9):2102-6. PubMed ID: 10232595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Photodynamic therapy of DNA mismatch repair-deficient and -proficient tumour cells.
    Schwarz VA; Hornung R; Fedier A; Fehr MK; Walt H; Haller U; Fink D
    Br J Cancer; 2002 Apr; 86(7):1130-5. PubMed ID: 11953861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential involvement of the human mismatch repair proteins, hMLH1 and hMSH2, in transcription-coupled repair.
    Leadon SA; Avrutskaya AV
    Cancer Res; 1997 Sep; 57(17):3784-91. PubMed ID: 9288788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance.
    de las Alas MM; Aebi S; Fink D; Howell SB; Los G
    J Natl Cancer Inst; 1997 Oct; 89(20):1537-41. PubMed ID: 9337351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes.
    Thibodeau SN; French AJ; Roche PC; Cunningham JM; Tester DJ; Lindor NM; Moslein G; Baker SM; Liskay RM; Burgart LJ; Honchel R; Halling KC
    Cancer Res; 1996 Nov; 56(21):4836-40. PubMed ID: 8895729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cooperation between p53 and hMLH1 in a human colocarcinoma cell line in response to DNA damage.
    Vikhanskaya F; Colella G; Valenti M; Parodi S; D'Incalci M; Broggini M
    Clin Cancer Res; 1999 Apr; 5(4):937-41. PubMed ID: 10213232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen.
    Taverna P; Liu L; Hanson AJ; Monks A; Gerson SL
    Cancer Chemother Pharmacol; 2000; 46(6):507-16. PubMed ID: 11138465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.